Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Oct 1, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

FDA Approves Varubi for Chemotherapy-Induced Nausea and Vomiting

 

FDA approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting.

Varubi, marketed by Tesaro Inc., is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing cancer chemotherapy.

Nausea and vomiting that occurs from 24 hours to up to 120 hours after the start of chemotherapy is referred to as delayed phase nausea and vomiting. Prolonged nausea and vomiting can lead to weight loss, dehydration and malnutrition in cancer patients leading to hospitalization.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter